Acelyrin is an innovative clinical-stage biopharma company that identifies, acquires, and accelerates the development and commercialization of life-changing therapies.
Acelyrin strives to redefine what is possible and quickly bring innovative therapies to bear against serious diseases.
Acelyrin was founded in 2020 by Robert F. Carey and Shao-Lee Lin. The company is headquartered in Los Angeles, California.
Acelyrin developed Izokibep, a unique antibody mimetic and potent interleukin-17A (IL-17A) inhibitor designed to overcome the limitations of existing monoclonal antibodies. Izokibep also has a unique molecular design that differentiates it from other IL-17A inhibitors.
Acelyrin also has entered into an agreement with Affibody AB to develop and commercialize izokibep.
Acelyrin is backed by AyurMaya, Surveyor Capital, Westlake Village BioPartners, Cowen Healthcare Investments, Decheng Capital, Marshall Wace, OrbiMed, andd others. The company completed a $250M Series B round on Nov 16, 2021. This brings Acelyrin's total funding to $258M to date.